Bromocriptine treatment in Parkinson's disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease is a neurodegenerative disorder affecting motor function.
• Dopamine receptor agonists are a potential treatment avenue.

Purpose of the Study:

• To evaluate the efficacy and safety of bromocriptine in Parkinson's disease patients.
• To determine the optimal dosage and side effect profile of bromocriptine.

Main Methods:

• A 12-week treatment period with bromocriptine in 31 Parkinson's disease patients.
• A double-blind, placebo-controlled trial comparing bromocriptine to placebo in 20 patients.
• Assessment of therapeutic effects on disability and akinesia scores.
• Evaluation of side effects and plasma growth hormone concentration.

Main Results:

• Bromocriptine demonstrated a slight therapeutic effect alone and an additional effect when combined with levodopa.
• A mean optimal dosage of 26 mg daily was established.
• Significant reduction in total disability and akinesia scores (P < 0.02) was observed in the bromocriptine group compared to placebo.
• The least disabled patients exhibited the greatest response.
• Observed side effects included nausea, vomiting, hallucinations, and involuntary movements, similar to levodopa.
• Minimal increase in plasma growth hormone was noted in Parkinson's patients.

Conclusions:

• Bromocriptine offers therapeutic benefits for Parkinson's disease, particularly in reducing disability and akinesia.
• Its side effect profile is comparable to levodopa.
• Bromocriptine may not be effective in patients unresponsive to levodopa or for managing end-of-dose akinesia.